salvage Lymph Node Dissection

PROCEDURE2 trials

Sponsors

Medical University of Vienna, University Hospital, Ghent

Conditions

Metastatic CancerOligometastatic CancerProstate CancerProstate Cancer MetastaticProstate Cancer Recurrent

Phase 2

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

Active, not recruitingNCT03569241

University Hospital, GhentMetastatic Cancer, Oligometastatic Cancer, Prostate Cancer +1

Start: 2018-04-27End: 2026-12-31Updated: 2024-12-09

Unknown Phase

Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy

CompletedNCT02974075

Medical University of ViennaProstate Cancer Recurrent

Start: 2016-08-31End: 2024-11-30Updated: 2025-05-14

Related Papers

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

2026-01-20

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.

2025-05-0524 citations

Safety and efficacy of salvage lymph node dissection in prostate cancer patients with nodal recurrence after radical prostatectomy: A prospective single center phase I/II study.

Journal of Clinical Oncology2025-02-10

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.

2023-10-0922 citations

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

2020-09-1432 citations

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer2020-06-0132 citations

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

2020-05-1264 citations

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

JAMA Oncology2020-03-261068 citations